Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
hq6VrSpmkp0mBV2z
